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Dentoalveolar regeneration involves a cascade of events regulated by early mitogenic 
and late-differentiational factors. It is necessary to develop a vehicle delivering 
multiple bioactive molecules to harmonize mitogenesis and osteogenic differentiation, 
in order to optimize dentoalveolar regeneration. This thesis aimed at designing and 
fabricating a delivery system to release platelet derived growth factor (PDGF, mitogen) 
and simvastatin (osteogenic differentiation promoter) in accordance with cascade of 
events during regeneration, in order to promote dentoalveolar regeneration in a 
preclinical model.  
 
To carry the two biomolecules, we utilized a coaxial electrohydrodynamic 
atomization (CEHDA) technique to fabricate double-walled PLGA (PDLLA) 
microspheres. The inherent properties of microspheres were characterized by confocal 
and scanning electronic microscopy, and the encapsulation efficiency, as well as the in 
vitro releasing profile of microspheres, were examined by ELISA and HPLC. For 
biocompatibility testing, microspheres encapsulating BSA-in-shell (XB), 
simvastatin-in-core with BSA-in-shell (SB), PDGF-in-shell (XP), simvastatin-in-core 
with PDGF-in-shell (SP), PDGF-in-core and simvastatin-in-shell (PS), were 





regeneration capability, microspheres were filled into critical-sized osseous defects on 
rat maxillae, and examined by micro-computed tomography (micro-CT) and histology, 
and defect without any microspheres implantation was designated as control (Ctrl).  
 
The microspheres have rounded morphology with distinct core-shell structure and 
high encapsulating efficiency. A fast-release of PDGF followed by slow-release of 
simvastatin was noted in SP-microspheres, whereas PS-microspheres have a parallel 
release profile. All microspheres demonstrated acceptable biocompatibility in vivo, 
with increased proliferation, reduced apoptosis, and reduced inflammation while 
PDGF or simvastatin was encapsulated. From the micro-CT assessment, 
SP-treated-specimens demonstrated highest bone volume fraction (BVF), tissue 
mineral density (TMD), trabecular thickness, and trabecular number among the 
groups at day 14. At day 28, elevated BVF, TMD and trabecular number was noted in 
SB-, XP- and SP-treated-specimens, but not in PS-treated-specimens. Descriptive 
histology revealed more trabecular bone formation in SP-treated-specimens than the 
other groups at day 14, and bone maturation was noted in XP- and 
SP-treated-specimens at day 28. 
 





PDGF for cell proliferation and delayed release of simvastatin with improved 
biocompatibility, and the sequential release of PDGF and simvastatin was able to 



















Chapter 1:  
Introduction 
 
1.1 Periodontal disease: an overview 
Periodontal diseases have traditionally been divided into those that involve only 
gingiva, so-called gingivitis, and those that are associated with the destruction of the 
underlying structures of the periodontium, so-called periodontitis [1]. The 
periodontium is referred to as the tooth-supporting apparatus, including gingiva, 
alveolar bone, periodontal ligament (PDL), and root cementum [1] (Figure 1).   
 
The characteristics of periodontitis are loss of connective tissue, resorption of alveolar 
bone, and formation of periodontal pockets. It is one of the most common 
inflammatory diseases in humans, and a leading cause of tooth loss in adults [1-3]. 
 
Periodontal disease is caused by specific bacteria in the periodontal pocket [1]. 
Socransky has developed a classification of oral microorganisms, the so-called 
Socransky classification. This classification divided the oral microorganisms into five 





orange, yellow, green, and purple complexes [4]; where the red complex consists of 
Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola, more 
frequently found in higher numbers in deeper periodontal pockets. The bacteria 
secretes numerous bacteria products in the periodontal pockets, such as endotoxins, 
which lead to cytotoxicity [5-7] and collagenase as well as protease, which cause 
destruction of collagens, proteoglycans and connective-tissue matrix [8, 9]. In 
addition, bacterial lipopolysaccharide can induce the destruction of bone by a direct 
effect on bone cells [10, 11]. As a consequence, extensive destruction of the 
periodontium may finally lead to tooth loss [1]. 
 
The current management of periodontal diseases mainly place emphasis on slowing 
the progression of the disease process, regenerating periodontium, including alveolar 
bone, periodontal ligament, and root cementum, and preventing recurrence of diseases 
[12]. The treatment generally starts by establishing excellent oral hygiene, followed 
by the removal of bacterial plaque and calculus to control inflammation and stop 
progressive bone loss. In the last two decades, various regenerative procedures have 
been evaluated to restore the lost periodontium. Among the surgical procedures, the 
regeneration of damaged periodontal structures with bone graft materials and guided 





outcomes are variable, depending on multiple factors such as defect size and type, 
patient age and education, genetics, and the operator skills [13, 14]. Some studies 
demonstrated that these therapies remain limited from both preclinical and clinical 
studies, especially in terms of cementum and functional PDL regeneration [15-17]. 
Complete repair and regeneration of functional hybrid periodontal tissues remains an 
elusive but laudable goal [15, 18]. To date, there is still no ideal therapeutic approach 
to cure periodontitis or to achieve predictable and optimal periodontal tissue 
regeneration [18]. The periodontal regeneration rather than repair remains the desired 
optimal outcome [19-22]. It is anticipated that tissue-engineering methods could 
overcome some of the limitations associated with the current clinically available 
strategies [23-26].  
 
1.2 Wound healing cascade 
The wound healing cascade takes place in four phases: clot formation, inflammation, 
proliferation, and maturation [27-30] (Figure 2).  
 
1.2.1  Clot formation 
Clot formation is the first step of healing, to stop bleeding and to reduce infection by 





migration and can temporarily protect the denuded tissues [28].  
1.2.2  Inflammation 
Inflammation takes place within 3 to 24 hours after the wound has been incurred. The 
inflammatory cells, predominantly neutrophils and monocytes, populate the clotting 
mechanism. These cells cleanse the wound of bacteria and necrotic tissue through 
phagocytosis and release of enzymes and toxic oxygen products [31]. 
 
1.2.3  Proliferation 
Within 3 days, the inflammatory reaction moves into late phase. Macrophages migrate 
into the wound area and secrete polypeptide mediators targeting cells involved in the 
wound-healing process for wound debridement. Growth factors and cytokines 
secreted by macrophages are involved in the proliferation and migration of fibroblasts, 
endothelial cells, and smooth muscle cells into the wound area [32].  
During proliferation phase, immature granulation tissue containing plump active 
fibroblasts forms. The fibroblasts produce an abundance type III collagen to fill the 







1.2.4  Maturation 
The granulation tissue next undergoes maturation and remodeling. Fibroblasts become 
more spindle-shape in appearance and produce type I collagen for the replacement of 
the provisional extracellular matrix. Approximately 1 week following wound healing, 
some fibroblasts mature into myofibroblasts and express a smooth muscle actin, 
which enables them to contract and reduce the size of the wound. For angiogenesis, 
endothelial cells migrate into the provisional wound matrix to form vascular tubes and 
loops, and as the provisional matrix matures, the redundant vessels formed in 
granulation tissue are removed by apoptosis, and type III collagen is largely replaced 
by type I collagen [27, 34].  
 
Maturation of the granulation tissue will lead to the regeneration or repair (scar 
formation) of the injured tissues. Whether the damaged tissues heal by regeneration or 
repair depends upon two crucial factors: the availability of cell type(s) needed; and, 
the presence or absence of cues and signals necessary to recruit and stimulate these 
cells [17]. 
 
1.2.5  Periodontal ligament healing 





mentioned above, and involves periodontal ligament as well as alveolar bone 
regeneration.  
The healing is initialized by the clot formation imposed onto the root surface in a 
seemingly random manner after treatment. Within minutes, a fibrin clot attached to 
the root surface is developed. Within hours, inflammatory cells, predominantly 
neutrophils and monocytes, accumulate on the root surface, and within 3 days the late 
phase of inflammation dominates the healing process as macrophages migrate into the 
wound followed by the formation of granulation tissue. At 7 days, collagen fibers 
adhesion may be seen at the root surface [30]. In about three weeks, the denuded root 
surface stimulates the differentiation of cementoblasts, which will deposit a hard 
tissue onto which new collagen fibers may be anchored [35]. Within few weeks of 
cementum deposition, the resorption on the root surface is initiated. The resorption 
process establishes a suitable substrate for anchorage of new collagen fibrils [36]. The 
repaired cementum deposits in the resorbed areas, thus completing the new 
attachment [37].  
 
1.2.6  Alveolar bone healing 
The dynamic of alveolar bone healing was studied by a tooth extraction model in dog 





tissue was formed. At 14 days, provisional connective tissue and woven bone 
formation was determined. The woven bone was in a finger-like projection and 
contained large number of osteoblasts. Bone was continuously undergoing bone 
remodeling, which was a complex process involving the resorption of bone by 
osteoclasts, followed by a phase of bone formation by osteoblasts [39]. At 6 months, 
the woven bone was then replaced by lamellar bone, which has a regular parallel 
alignment of collagen into sheets and was mechanically stronger than woven bone. 
 
1.2.7  Growth factors involved 
Examples of growth factors found locally in bone and healing tissues include 
platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-b), 
acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), 
insulin-like growth factors (IGF-I and IGF-II), and the bone morphogenetic proteins 
(BMPs) [40]. The PDGF is a potent mitogen and chemoattractant for many cell types, 
such as fibroblasts and osteoblasts [41]. The actual maturation of the bone from 
disorganized woven bone into a mature lamellar bone involves IGF and BMP [42]. 
 
1.3 Current regeneration approaches 





regeneration, bone grafts and bioactive molecules-driven regeneration [43].  
 
1.3.1  Guided tissue regeneration (GTR) 
The clinical applications of GTR in periodontics involve the placement of a 
cell-impermeable barrier membrane between detoxified root surface and the 
crevicular epithelium in order to enable the repopulation of cells from the periodontal 
ligament to the root surface [44]. The principle of GTR and its achievements in both 
preclinical and clinical trials over the past three decades have been comprehensively 
reviewed [13, 45-48]. Normally, the periodontal defect, if left empty after open flap 
debridement, will fill with epithelial cells and fibroblasts, which generates a core of 
fibro-epithelial tissues that ultimately prevent the sequential regeneration of true 
periodontal tissue. The GTR technique therefore employs a barrier membrane to 
prevent epithelium down growth and allow fibroblast migration into the wound area, 
thereby also maintaining the space for target periodontal tissue regeneration [45, 46, 
48].  
 
GTR has been applied in many clinical trials for the treatment of various periodontal 
defects, such as intrabony defects [49], furcation involvement [50, 51] and localized 





periodontal practices today. Indeed, histological analysis of GTR-mediated healing 
demonstrates that new connective tissue attachment to the root surface forms with 
minor contributions from new cementum and bone formation, which, by definition, is 
not true periodontal tissue regeneration. As a result, it is still difficult to draw general 
conclusions about the clinical benefits of GTR with the currently available and limited 
evidence. 
 
1.3.2  Bone grafts 
Bone grafts aim to restore the height of the alveolar bone around a previously 
diseased tooth. It was believed that growth factors in the graft were able to release 
into the implanted area to promote the wound healing and tissue regeneration. In 
general, there are three types of bone grafts; autogenic, allogenic and xenogenic grafts. 
A number of reviews have already summarized the advantages and disadvantages of 
different grafts as well as bone substitutes [13, 53, 54]. 
 
Currently, autogenously harvested bone grafts are most commonly used for the 
replacement of bone material in bone-repair-related research, especially due to the 
absence of the immunogenic reaction post-surgically. Disadvantages with the use of 





for an additional invasive surgical procedure that may result in donor-site morbidity, 
chronic postoperative pain, hypersensitivity and infection. 
Allogenic and xenogenic grafts are widely available and do not require a second 
surgical site for the patient to harvest autogenous bone. However, allogenic and 
xenogenic grafts will increase the risks of immunological reactions. In this regard, the 
grafts must undergo processing techniques such as lyophilization, irradiation or 
freeze-drying to remove all immunogenic proteins. As a consequence, the 
osteoinductive and osteoconductive potentials of allografts and xenografts will be 
decreased as compared with autografts [55]. 
 
1.3.3  Bioactive molecules-driven regeneration  
Wound healing is regulated by a complex signaling network involving numerous 
growth factors, cytokines, and chemokines. The application of morphogenetic or 
mitogenic growth factors to support bone formation at localized alveolar ridge defects 
has become an area of increasing interest [56]. The currently used bioactive molecules 
in periodontal diseases include PDGF (GEM 21S, Osteohealth, Shirley, NY, USA), 
BMP and enamel matrix derivatives (Emdogain, Straumann, Andover, MA, USA). 





dentoalveolar regeneration.  
 
1.3.3.1  Platelet-derived growth factors in periodontal bone regeneration 
Within the family of growth factors, platelet derived growth factor (PDGF) is the 
class of proteins that has been extensively investigated particularly with reference to 
the regeneration of periodontal tissues [57-61]. The PDGF receptor signaling has been 
reported to play an important role in the regulation of proliferation and migration of 
cells including osteoblasts and fibroblasts [62, 63]. It has been reported that 
PDGF-BB stimulates the proliferation of osteoblasts and fibroblasts [64, 65].  
 
In the study on beagle dogs, Lynch et al. [66] showed that the PDGF promotes new 
bone formation around periodontal bony defects. The results also demonstrated a 
continuous layer of osteoblasts lining the newly formed bone in the sites treated with 
PDGF compared to the sites without PDGF treatment [66]. Since then, several clinical 
[59-63, 67] and experimental studies [68-72] have been performed to investigate the 
potency of PDGF in the treatment of periodontal bony defects.  
 
Simion et al. found that rhPDGF-BB-infused matrix significantly enhanced bone 





model [70]. The rhPDGF-BB was found to exert a potent chemotactic effect on 
osteogenic cells present in the periostium. 
 
In addition, Schwarz et al. conducted a preclinical study to evaluate the healing 
outcomes following horizontal ridge augmentation [69]. The rhPDGF-BB treated 
group demonstrated better results in terms of mineralized tissue and total augmented 
area at 3 weeks than the control group. Taken together, the promising preclinical 
evidence of PDGF therapy established the foundation for therapeutic evaluation of 
PDGF in clinical applications.  
 
An early human clinical trial to evaluate the effect of rhPDGF/IGF treatment applied 
to osseous periodontal defects was reported by Howell et al. [59]. The experimental 
sites received direct application of the growth factors contained in a methylcellulose 
matrix to improve retention. At nine months post-surgery, the growth-factor-treated 
sites showed a statistically significant increase in alveolar bone formation as 
compared with untreated control sites. Average bone height for the PDGF/IGF group 
was 2.08 mm and 43.2% osseous defect fill was achieved, as compared with 0.75 mm 






Recently, a clinical study conducted by Nevins et al. had demonstrated that the use of 
purified recombinant human platelet-derived growth factor (rhPDGF-BB) was safe 
and effective in the treatment of periodontal osseous defects in patients [61]. The 
study found that treatment with rhPDGF-BB stimulated a significant increase in the 
rate of clinical attachment level gain, reduced gingival recession at 3 months 
post-surgery, and improved bone fill as compared to a β-TCP bone substitute at 6 
months. The PDGF has also been used for the bone regeneration around the dental 
implants [57]. 
 
1.3.3.2  Simvastatin in bone regeneration 
Simvastatin, a specific competitive inhibitor of 3-hydroxy-2-methyl-glutaryl 
coenzyme A (HMG-CoA) reductase, is a widely-used anti-hyperlipidemia drug [73, 
74]. In recent years, the effect of simvastatin on bone tissue has received particular 
attention. Mundy et al. first reported that simvastatin stimulated in vivo bone 
formation in rodents and increased new bone volume in cultures from mouse calvaria 
[75]. Several studies further demonstrated that simvastatin is able to modulate bone 
formation by increasing the expression of BMP-2 and angiogenesis on mouse calvaria 
and rat mandibles [75-79], providing a new direction in the field of periodontal 





differentiation pathway [80], thus considered to promote osteogenesis in the later 
stage of bone regeneration. Recently, simvastatin was found to support 
BMP-2-induced osteoblast differentiation through antagonizing TNF-α-to-MAPK 
pathway and augmenting Ras/Smad/Erk/BMP-2 signaling pathway [81-83].  
 
Simvastatin is shown to increase cancellous bone volume, bone formation rate, and 
cancellous bone compressive strength in vivo [84]. Various animal studies showed that 
simvastatin assists in bone regeneration, minimizes alveolar bone loss and has 
protective features against the impact of periodontitis on attachment apparatus and 
alveolar bone when delivered or applied locally [78, 85-88]. The successful use of 
simvastatin to promote bone formation in vivo depends on the local concentration, and 
there have been persistent efforts to find an appropriate delivery system [89].  
 
A clinical trial using simvastatin on patients with chronic periodontitis showed that 
there was a greater decrease in gingival index and probing depth, and more clinical 
attachment level gain with significant intrabony defect fill at sites treated with scaling 







1.4 The tissue engineering scaffold 
Drug delivery systems are designed in order to enable the growth factor to efficiently 
exert its biological effects [91, 92]. Current delivery systems still suffer from several 
limitations for clinical periodontal applications such as loss of bioactivity, limited 
control over dose administration, nontargeted delivery, and/or lack of availability. The 
development of a suitable scaffold to overcome these limitations is still needed. 
 
It is well established that cells reside, proliferate, and differentiate inside the body 
with a complex 3D environment, indicating that an extracellular matrix (ECM) is a 
pivotal factor with a significant role in supporting or restoring periodontal 
regeneration. 
 
An artificial ECM, carried out by scaffolding materials, therefore is a prerequisite of 
most tissue regeneration strategies. Scaffolds are porous, degradable structures 
fabricated from either natural materials (collagen [93-96], fibrin [97, 98], or synthetic 
polymers [99-101]). Scaffolds can be sponge-like sheets, gels, micro/nano-spheres, or 
highly complex structures with intricate networks of pores and channels fabricated 
using new material-processing technologies. Virtually all scaffolds used in tissue 





replaced by new tissue [102]. 
 
To achieve the functions of a scaffold in tissue engineering, the scaffold should meet 
a number of requirements, such as interconnected micropores for cell migration and 
ingrowth, optimal porosity with adequate surface area and mechanical strength, and 
controlled absorption kinetics or degradation [97, 98, 100, 103]. 
 
1.5 Towards the delivery of multiple growth factors 
Reconstructive strategies do not always yield satisfactory outcomes [104]. The basis 
for tissue regeneration is the utilization of engineering techniques that mimic the 
wound healing cascade, by providing suitable biochemical and physico-chemical 
factors [105, 106]. Since the wound healing cascade was discovered, it is currently 
accepted that the self-healing capacity of patients can be augmented by artificially 
accelerating the proliferation and differentiation of the recruited or implanted cells via 
the integration of growth factors and cytokines [105-108]. To achieve this goal, it is 
indispensable to provide cells with a local biochemical and mechanical niche 
mimicking the natural environment in which they can proliferate and differentiate 







With an improved understanding of the critical pathways involved in the development 
of integrated tissues, the role of growth factors in the wound healing cascade, and the 
expansion of their availability through recombinant technologies, the use of growth 
factors is an increasingly important strategy to repair or regenerate damaged/ diseased 
tissue and is a leading component of tissue engineering approaches [108, 111, 112]. 
To be effective as a therapeutic agent, a growth factor has to reach the site of injury 
without degradation, and then, it has to remain in the target location sufficiently long 
to exert its action(s) [25]. Growth factors that are provided exogenously in solution 
into the site to be regenerated are generally not effective because growth factors tend 
to diffuse away from wound locations and are enzymatically digested or deactivated 
[25, 105-110]. There is increasing evidence that enabling growth factors to exert their 
biological function efficiently in tissue engineering requires the design and 
development of release technologies that provide controlled spatiotemporal delivery 
of key signaling molecules, and prevent unwanted and potentially harmful side-effects 
[113].  
 
The understanding of the critical pathways in tissues development is leading to 





deliver and the dose and timing of delivery, for the regeneration of a number of 
homologous tissues [104]. In the natural wound healing process, responding cells are 
regulated by a coordinated cascade of events with several growth factors and 
signaling molecules in a time- and concentration-dependent fashion, which has been 
clearly established for bone repair [114-117]. This suggests that appropriate 
presentation of multiple regulatory signals may be a prerequisite for effective tissue 
engineering strategies; thus, controlled delivery of various combinations of growth 
factors is a compelling method for the future [104]. 
 
Although the delivery of single growth factor has been well-studied, the strategies 
involved in delivery of two or more growth factors have not been as extensively 
examined [113]. Research on this concept has begun to harness advances in 
biomaterials and basic biology to yield next generation medical devices to replace 
tissue function and new treatment approaches to stimulate or augment endogenous 
repair mechanisms [104]. Appropriately designed release technology may in turn 
reduce the amount of protein required to achieve a desired effect, which essentially 
increases the potency of the growth factors in some cases [111, 112, 118, 119]. The 
incorporation of multiple growth factors into cell-based tissue engineering systems, 





regeneration [113]. Since the first attempt of dual growth factors delivery through a 
polymeric system by Richardson et al. [120] concerted efforts have been and still are 
being made to achieve this ambitious purpose [113]. 












HYPOTHESIS AND OBJECTIVES 





Chapter 2:  
Hypothesis and Objectives 
 
2.1 The hypothesis of this study 
The study was designed to test the following hypothesis: 
By mimicking the physiological events during wound healing, the combination of the 
fast release of PDGF and the slow release of simvastatin will promote dentoalveolar 
regeneration. 
 
2.2 The objectives of this study 
The detailed objectives of this study are as following: 
(1) To fabricate a delivery system to control release PDGF and simvastatin. 
The CEHDA technique was used to fabricate double-walled polymeric microspheres 
in order to carry PDGF and simvastatin to achieve the release profile in accordance 
with the physiological events [121] (i.e., fast release profile of PDGF to promote early 
mitogenesis, and slow release profile of simvastatin to promote later osteogenic 
differentiation). 
 




(2) To examine the biocompatability of the fabricated microspheres. 
The microspheres were implanted subcutaneously and the cell viability (i.e. 
inflammation, proliferation and apoptosis), as well as the thickness of fibrotic tissue 
was examined by immunohistochemistry. 
 
(3) To investigate the regenerative ability of fabricated microspheres in a preclinical 
osseous defect model. 
A critical-size bony defect was created on the rat maxilla and filled with (XB, SB, XP, 
PS, and SP) or without microspheres. The outcome of regeneration was evaluated 
through descriptive histology and volumetric analysis from micro-computed 
tomography (micro-CT) data with 6 parameters (bone volume fraction, bone mineral 
density, tissue mineral density, trabecular thickness, trabecular number and trabecular 
separation).   












MATERIALS AND METHODS 
 





Materials and Methods 
 
3.1 Fabrication of microspheres 
3.1.1  The protocol of microspheres fabrication 
The microspheres of distinct core/shell structures were fabricated by coaxial 
electrohydrodynamic atomization (CEHDA) technique in a disinfected hood. The 
schematic diagram of the set-up of CEHDA is shown in Figure 3.  
 
Briefly, the microspheres with the core-shell structure were respectively made up of 
10% PDLLA (Mw
 
= 24,300-75,000) and 10% PLGA (50:50, Mw
 
= 31,300-43,500) 
(Lactel Absorbable Polymers, Pelham, AL, USA
 
) in dichloromethane solution (DCM, 
Tedia, Fairfield, OH, USA). As for loading of the biomolecules, 1 mg simvastatin 
(Pharmaceutical Simtin®-20, National University Hospital of Singapore, Singapore) 
(hydrophobic agent) was dissolved in corresponding matrix. Meanwhile, the 
hydrophilic agent, PDGF-BB (Luitpold Pharmaceuticals, Inc., Wilmington, USA) or 
bovine serum albumin (BSA, Sigma-Aldrich Corporation, St. Louis, MO, USA) was 
firstly dissolved in DI water and added to the core or shell phase. The mixture was 
sonicated at 20-30% amplitude for about 60 s with Sonics Vibra cell to form an 




emulsion, and the effectiveness was controlled by the amplitude of oscillation of an 
ultrasonic transducer. Loaded solutions were then transferred to syringes connected 
with the coaxial needle (Popper and Sons, Lake Success, NY, USA), which is made of 
316L stainless steel. The outer capillary has an outer diameter of 0.72 mm and an 
inner diameter of 0.50 mm. The inner capillary has an outer diameter of 0.40 mm and 
an inner diameter of 0.20 mm. The spraying process was pre-tested and monitored to 
confirm that the emulsion is still stable during this process. Two programmable 
syringe pumps (KD Scientific, Holliston, MA, USA) were used to inject core and 
shell phase solutions at a specific rate into the inner and outer capillary of the coaxial 
needle. A voltage generator (Glassman High Voltage Inc., High Bridge, NJ, USA) 
supplies a high voltage to the nozzle via a crocodile clip. In order to stabilize the 
electric field around the nozzle, another high voltage is applied to the ring (5 cm in 
diameter) surrounding the nozzle. The nozzle voltage was fixed at 6.5 kV while the 
ring voltage was maintained at 3.5 kV, and the flow rates for the core and shell phases 
were maintained at 1.8 and 2 mL/h respectively. The resultant microspheres collected 
on the aluminum foil were then maintained in a freeze-dryer for 3 days. In order to 
visually differentiate the core and shell structure, a fluorescent dye coumarin 6 
(Sigma-Aldrich Corporation, St. Louis, MO, USA) was added only in the shell 
matrix. 




3.1.2  Characterization of microspheres 
The size and surface morphology of fabricated microspheres were examined by 
scanning electron microscopy (SEM) (JSM 5600LV, JEOL Technics Co. Ltd, Tokyo, 
Japan), and the analysis of particle diameter was done by SMILEView software 
(Bioprecision Diagnostics Ltd, Somerset, UK) at n>50. Confocal laser scanning 
microscope (Zeiss LSM 510) was employed to observe the distribution of coumarin 6 
in microspheres. The dye distribution can be used as an indicator of the extent of 
mixing of the inner and outer flows at the tip of the coaxial needle.  
 
3.1.3  Encapsulation efficiency and in vitro release 
To determine the encapsulation efficiency of simvastatin and PDGF or BSA in 
microspheres, 20.0 mg of double-walled microspheres were dissolved in 1.0 mL 
DCM and subsequently 1.0 mL fresh PBS was added, vortexed, and centrifuged at 
9,000 rpm for 20 min. The aqueous layer was collected, and two more extraction 
cycles were again performed to maximize the extraction efficiency. PDGF or BSA 
concentration in aqueous phase and the simvastatin concentration in organic phase 
were determined by ELISA (R&D system, Minneapolis, MN, USA), Micro BCA 
protein assay kit (Pierce Chemical, Rockford, IL) and by high performance liquid 
chromatography (HPLC, HP1200, Agilent Technologies, Palo Alto, CA, USA), 




respectively. For the HPLC analysis, extracted simvastatin was reconstituted in 
mobile phase (70% acetonitrile) and filtered through a 0.22 µm syringe filter. A 
reverse-phase Poroshell 120 column (EC-C18, 4.6×75 mm, 2.7 µm) was used at a 
flow rate of 2 mL/min. 10 µL of sample was injected by an auto-sampler and the 
column effluent was detected at 238 nm with a UV/Vis detector.  
 
For in vitro release test, 50.0 mg core/shell microspheres was loaded in 10.0 mL of 
PBS (pH 7.4) containing 0.05% of Tween 80. The whole system was then placed in an 
orbital shaker bath (GFL
®
 1092, Burgwedel, Germany) maintained at 37
°
C and 120 
rpm. At 1, 3, 5, 7, 10 and 14 days, 8.0 mL of the incubated medium was withdrawn 
and replaced with 8.0 mL of fresh medium. Simvastatin in the resultant release 
medium was extracted with DCM, and then reconstituted with mobile phase (70% 
acetonitrile) for HPLC analysis as described above. PDGF and BSA concentration in 
the resultant release medium were determined by ELISA and Micro BCA protein 
assay kit, respectively according to the manufacturer’s instruction. All the 
measurements were done in triplicate. This well-established in vitro release protocol 
has been widely used in microsphere drug delivery studies [122], and a previous 
investigation demonstrated that this in vitro release scheme was parallel to the in vivo 
release profile [123]. 




3.2 In vivo biocompatibility 
3.2.1  Animal model 
Twenty eight-week-old (weight about 300 g) Sprague-Dawley male rats were utilized 
in this study according to the guidelines of Institutional Animal Care and Use 
Committee (IACUC) of the National University of Singapore (NUS). All procedures 
were performed under the generalized coverage of ketamine (70 mg/kg) and xylazine 
(10 mg/kg), and instruments were sterilized before and after microspheres delivery. 
Microspheres encapsulating BSA-in-shell (XB), simvastatin-in-core and BSA-in-shell 
(SB), PDGF-in-shell (XP), PDGF-in-core and simvastatin-in-shell (PS), and 
simvastatin-in-core and PDGF-in-shell (SP), were sterilized by UV overnight. Each 
kind of microspheres was randomly inserted subcutaneously in either left or right side 
of the back of rats respectively (n=4), and the skin wound was closed by using the 
surgical clips. The rats were sacrificed, and tissues were harvested at day 10 and 14 
post-insertion.  
 
3.2.2  Histology assessment 
Each implanted area was collected and fixed in 10% formalin for 3 days, then 
embedded in paraffin, and cut into 5 µm in thickness. Specimens were stained with 
Heamatoxylin and Eosin (Polysciences, Warrington, PA, USA) for descriptive 




histology and quantifications of inflammatory cells and thickness of the fibrotic wall. 
Inflammatory cells were quantified based on the cellular characteristics in three 
randomly-selected areas under 400× magnification in each specimen, and the results 
are presented as the percentage of inflammatory cells to the total amount of cells. The 
thickness of fibrotic wall was measured from 10 randomly-selected areas under 200× 
magnification.  
 
Cell viability was assessed by immunohistochemistry, the staining was done by using 
a Cell & Tissue Staining Kit (R & D Systems, Minneapolis, MN, USA) for the 
expression of proliferating cell nuclear antigen (PCNA) and TUNEL technology 
utilizing an in situ Cell Death Detection Kit (POD, Roche Applied Science, Basel, 
Switzerland). Following the blocking of nonspecific binding with serum, the sections 
were incubated with the following first primary antibodies: anti-proliferating cell 
nuclear antigen (anti-PCNA, dilution 1:200, Abcam, PLC, Cambridge, UK) and 
antibody provided in the in situ Cell Death Detection Kit (dilution 1:9, Roche Applied 
Science) overnight at 4°C, and subsequently incubated with the correspondently 
biotinylated secondary antibodies for 1 h at room temperature. The color were 
developed by 3,3-diaminobenzidine (DAB), and sections were finally counterstained 
with hematoxylin after they were applied HRR-Horse-Radish Perioxidase for 30 min. 




Quantifications of proliferating and apoptotic cells were performed in three randomly 
selected areas under 400× magnification in each specimen, and the results are 
presented as the percentage of cells with positive signals to the total amount of cells. 
All images were acquired by a Leica DMD108 system (Leica DMD108 system, Leica 
Microsystems GmbH, Wetzlar, Germany). 
 
3.3 Preclinical Osseous Defect Model and Study Design 
3.3.1  Animal model and study design 
All animal procedures were performed under the protocol 057/10 approved by the 
IACUC of NUS. The study design is shown in Figure 4A and an osseous defect model 
was created to analyze the capability of alveolar bone regeneration (Figure 4B).  
 
The maxillary first molars (M1) of 36 4-week-old male Sprague-Dawley rats were 
extracted under general anesthesia covered by ketamine (70 mg/kg) and xylazine (10 
mg/kg). After 4 weeks of socket wound healing, a critical-sized osseous defect was 
created in the M1 edentulous ridge next to the mesial aspect of the second molar (M2). 
Briefly, a 2.0 mm-in-diameter and 1.0 mm-in-depth osteotomy was firstly created in 
the edentulous ridge using a customized drill. Microspheres encapsulating XB, SB, 
XP, PS or SP were placed to completely fill the defects and the wound was closed by 
approximating the gingival tissues and sealed with cyanoacrylate gel (Histoacryl, 




TissueSeal, Ann Arbor, MI, USA). We also created a control which without any 
implantation of microspheres (Ctrl). The animals were sacrificed at 14 or 28 days 
post-surgery. Maxillae were harvested and fixed in 10% neutral formalin for 3 days, 
and stored in 70% ethanol for the subsequent micro-CT assessment. 
 
3.3.2  Volumetric micro-CT measurement 
Scans were acquired on a Siemens Inveon CT (Siemens Healthcare, Erlangen, 
Germany
 
) at 2 × 2 binning and high magnification, achieving an ideal dynamic range 
and an effective voxel size of 19.54 µm. Images were reconstructed with no 
downsampling, using the Shepp-Logan algorithm and beam-hardening correction as 
recommended by the manufacturer. Customized software written in MATLAB (Natick, 
MA, USA) was used to load and segment the image volumes. The region of interest 
(ROI) was defined as a round area with a diameter of 2.0 mm and a depth of 1.0 mm 
(Figure 5). The boundary of ROI was identified by the distinct difference of the 
mineral density, whereby the native bone demonstrated a higher density than the 
neogenic bone [104]. The ROI was then segmented to the foreground (bone) and 
background (soft tissue) by a local edge-specific algorithm [104], and the bone 
volume fraction (BVF, bone area/total area), bone mineral density (BMD), tissue 
mineral density (TMD), and the trabecular analysis (trabecular thickness, trabecular 




number and trabecular separation) of the ROI was calculated using CT-analyzer 
software (Skyscan, Antwerp, Belgium). 
 
3.3.3  Histology assessment 
Specimens were decalcified with 12.5% EDTA (pH7.4) for 3 weeks after micro-CT 
scanning. Specimens were then embedded in paraffin, cut into 5 µm thickness, and 
stained with Hematoxylin and Eosin for descriptive histology assessment. All images 
were acquired by a Leica DMD108 system (Leica DMD108 system, Leica 
Microsystems GmbH, Wetzlar, Germany).  
 
3.4 Statistical analysis 
Statistical analysis was performed utilizing statistical software (GraphPad Software 
Inc., La Jolla, CA, USA). Data were pooled according to the experimental groups and 
presented as mean ± standard error of measurements. The differences in micro-CT 
measurements and quantitative histological analysis were compared by unpaired 





















4.1 Characterization of microspheres 
4.1.1  The morphology 
The uniform-sized microspheres (18-20 µm in diameter) were successfully fabricated 
by CEHDA technique (Figure 6). The morphology of microspheres was determined 
by SEM (Figure 6). The microspheres in each group demonstrated a regular rounded 
in morphology with a rough surface and porous structure.  
 
4.1.2  The core/shell structure 
The core/shell structure of the microspheres was verified by confocal laser scanning 
microscope (Figure 7). A distinct core-shell structure can be seen under confocal 
microscopy. The green fluorescent ring-shape shell was seen due to the fluorescent 
dye coumarin 6 added to the shell solution. No green fluorescence was found in the 








4.1.3  Encapsulation efficiency of biomolecules in microspheres 
The core/shell structured microspheres with simvastatin (hydrophobic) encapsulated 
in the core and PDGF (hydrophilic) encapsulated in the shell (SP), and microspheres 
with PDGF-in-core and simvastatin-in-shell (PS), were successfully fabricated by 
CEHDA. Concurrently, microspheres encapsulating XB, SB, and XP, were also 
developed for comparison (Table 1). 
 
As summarized in Table 1, the encapsulation efficiencies (EE) of simvastatin are 
about 80-90% in both simvastatin-in-core (SB and SP) and simvastatin-in-shell (PS) 
samples. The EE of PDGF in the PDGF-in-shell samples (XP and SP) is about 60%, 
whereas in the PDGF-in-core sample (PS) the EE is about 96%. The BSA has a similar 
EE to PDGF, which is about 60% when BSA encapsulated in the shell (XB and SB 
sample). 
 
4.1.4  In vitro release of biomolecules from microspheres 
Sample XB and SB represent a significant initial burst of BSA with more than 50% 
released within the first 3 days (Figures 8A and B). The release was almost complete 
in 7 days. In contrast, the initial burst of simvastatin was minimal. Only about 30% of 





approximately 50% in a 14-day time window. Similar release results were indicated 
for sample XP and sample SP with PDGF in substitute of BSA (Figures 8C and E). 
The initial burst of PDGF from sample XP and SP was about 80% at day 7, while the 
release profile was linear for simvastatin with about 50% being released after 14 days. 
The sample SP demonstrated sequential PDGF release followed by simvastatin. 
Compared to sample SP, the release of biomolecules from sample PS was relatively 
straightforward (Figure 8D). The release profiles of simvastatin and PDGF were well 
coupled, although the release rate of PDGF is slightly lower than simvastatin from 
day 3 to day 14. Different from the release pattern of samples SB and SP (Figure 8B 
and E), the release pattern of PS was classified as a parallel release (Figure 8D). 
 
4.2 Biocompatibility of the microspheres 
4.2.1  Descriptive histology 
The evaluation on the biocompatibility of microspheres was based on the observed 
inflammatory and healing responses after implantation [124]. Generally, fibrous tissue 
encapsulating residual polymers with minimal inflammatory cell infiltrate was noted 
in all specimens, and increasing cellularity without significant elevation of 
inflammation was indicated in the specimens with microspheres encapsulating PDGF 





At day 14, a mild increased infiltration, predominantly lymphocytes and a few plasma 
cells, was observed in most specimens (Figure 10), especially in 
SB-treated-specimens (Figure 10B). Therefore, inflammation appeared to be relieved 
when combining with PDGF delivery, and significant angiogenesis was noted in both 
PS- and SP-treated-specimens (Figures 10D and E). No signs of acute inflammation 
or abscess formation were noted in any of the specimens. 
 
4.2.2  Density of inflammation and cell viability assessment 
The biocompatibility was further examined by the density of inflammation and cell 
viability, including the proliferation profile by PCNA staining, and apoptosis by 
TUNEL staining. The images of PCNA and TUNEL staining at 10 days after 
implantation were shown in Figures 11 and 12, respectively. Quantitative 
measurements revealed that encapsulating bioactive molecules (both simvastatin and 
PDGF) can achieve a higher percentage of proliferating cells within the implanted site 
at day 10 (Figure 13). A significant difference of proliferating cells compared to the 
XB control was noted for SB-, XP-, and SP-treated-specimens, and inflammation was 
significantly reduced in XP-treated-specimens compared to the XB control (Figure 
13). In contrast, the results from TUNEL staining revealed scant distribution of 





The images of PCNA and TUNEL staining at 14 days after implantation are shown in 
Figures 14 and 15, respectively. At day 14, SP-treated-specimens still tended to 
demonstrate a higher proliferating profile than all of the other groups examined, 
however, there was no significant difference of proliferating cells between any 
bioactive molecules-loading group and the control group (Figure 16). The density of 
inflammation appeared equivalent among all groups (Figure 16). A slightly elevated 
expression of apoptotic cells were found in the control group, especially compared to 
XP-treated and PS-treated specimens (Figure 16). Bioactive molecules appeared to 
reduce cell apoptosis, and PS-treated-specimens demonstrated significantly fewer 
apoptotic cells than the control at both day 10 and 14 (Figures 13 and 16).  
 
The images of fibrotic wall around the microspheres at 10 and 14 days after 
implantation were shown in Figures 17 and 18, respectively. The thickness of the 
fibrotic wall tended to increase in SB-treated-specimens at day 10, but decrease in PS- 
and SP-treated-specimens at day 14 (Figure 19). 
 
4.3 Preclinical osseous defect study 
4.3.1  Volumetric micro-CT assessment 





in Figures 20A and B, respectively. The images from the sagittal plane are shown in 
Figure 21. 
  
At day 14, there was a trend of increasing BVF, TMD, trabecular thickness and 
trabecular number in XP-, PS- and SP-treated-specimens compared to controls. The 
BVF of SP-treated specimens was 35.2 ± 17.7 %, which was the highest among the 
groups and significantly higher than the Ctrl- (7.4 ± 3.9 %, p < 0.01) and XB-treated 
specimens (9.4 ± 4.1 %, p < 0.01). The SP-treated specimens demonstrated the 
highest TMD (328.7 ± 107.4 mg/cc), and was significantly higher than the Ctrl- 
(206.7 ± 105.8 mg/cc, p < 0.05) and XB-treated specimens (165.9 ± 49.9 mg/cc, p < 
0.05). The trabecular analysis revealed that SP-treated specimens had the highest 
trabecular thickness (0.23 ± 0.06 mm), and were significantly higher than both Ctrl- 
(0.16 ± 0.03 mm, p < 0.01) and XB-treated specimens (0.18 ± 0.03, p < 0.05). The 
trabecular number in SP-treated specimens was also the highest (1.65 ± 0.34 1/mm) 
among the groups with statistically significant to the Ctrl- (0.43 ± 0.18 1/mm, p < 
0.001) and XB-treated specimens (0.51 ± 0.21 1/mm, p < 0.001) (Figure 22). 
PS-treated-specimens demonstrated significantly higher BVF, trabecular thickness 
and trabecular number than controls. The SB-treated-specimens showed slight 





trend of trabecular separation in SP- and PS-treated specimens as compared to 
controls. 
 
At day 28, elevated BVF, TMD and trabecular number was noted in SB-, XP- and 
SP-treated-specimens but not in PS-treated-specimens (Figure 23). 
SP-treated-specimens demonstrated highest BVF (44.5 ± 4.2 %) among the groups 
and significantly higher than XB-treated specimens (13.9 ± 7.6 %, p < 0.01). SB- and 
XP-treated specimens showed significant increase of BVF (37.5 ± 5.1 % and 44.1 ± 
7.6 %, respectively) compared to XB-treated specimens. The PS-treated specimens, 
however, did not have much increase of BVF at day 28 (32.3 ± 22.1 %). The TMD of 
SB-, XP- and SP- were 372.2 ± 32.4 mm/cc, 431.2 ± 57.9 mm/cc and 413.1 ± 34.4 
mm/cc respectively which were significantly higher than the XB-treated specimens 
(183.5 ± 60.4 mm/cc, p < 0.05). The trabecular thickness was increased in all groups 
especially in SB-, XP- and SP-treated specimens (0.29 ± 0.06 mm, 0.34 ± 0.06 mm 
and 0.34 ± 0.03 mm respectively) these were again significantly higher than the 
XB-treated specimens (0.19 ± 0.06 mm, p < 0.05) . SB- and XP-treated specimens 
demonstrated significant increase of trabecular number (1.3 ± 0.2 1/mm and 1.3 ± 0.4 
1/mm respectively, p < 0.05). A decreasing trend of trabecular separation was also 





4.3.2  Descriptive histology 
Slight inflammatory cells infiltration was noted in each group at day 14. The front of 
osteogenesis is shown in Figure 24. Generally, newly-formed trabecular bone were 
fromed from the border accompanying with polymer residues distributing in the 
defect. XB-treated specimens demonstrated scanty new bone within the defect, and 
scatter bone distribution was found in SB-treated specimens. The XP-treated 
specimens demonstrated slightly more trabecular bone than SB-treated specimens. 
The PS- and SP-treated specimens revealed more bone formation and higher degree 
of trabecular thickness than the other groups. In addition, the reversal lines were also 
noted in the PS- and SP-treated specimens. 
 
At day 28, fewer inflammatory cells were found within the defect. In general, the 
newly-formed bone became mature with higher trabecular thickness and less 
trabecular separation (Figure 25). There were cell bundles lining on the newly-formed 
bone in Ctrl specimens. In XB-treated-specimens, bone formation appeared to be 
slightly greater than Ctrl specimens. The newly-formed bone in SB-treated-specimens 
was greatly increased compared to controls (i.e., Ctrl and XB-treated specimns). XP- 
and SP-treated-specimens demonstrated elevated bone volume and trabecular 





specimens. The PS-treated-specimens had less newly-formed bone than SB-, XP- and 
SP-treated-specimens. Moreover, an increase in cell density was noted in 





















Regeneration of damaged periodontal tissues is the ultimate goal for periodontal 
treatment, and delivering local signals in accordance with the dynamics of healing is 
capable of facilitating the process of regeneration [26]. As the wound repair involves 
a cascade of events with the coordination of multiple signals [26], combinational 
release of multiple signals can potentially render a more favorable and predicable 
therapeutic outcome than single intervention that was currently used.  
 
5.1 Fabrication of microspheres 
Since the biomolecules have the nature of fast degradation and diffusion rate in vivo, 
it is necessary to encapsulate the biomolecules in order to modulate those events 
[119]. In the present study, microspheres were utilized to carry and control the 
release of PDGF or simvastatin. The CEHDA technique allowed us to encapsulate 
two different types of biomolecules in one single step. The releasing profile of 
biomolecules was varied based on the difference of degradation rate of polymer used, 
configuration of the microsphere, and hydrophilicity of carried molecules. In the 





biomolecules released more slowly than shell-loaded one [121], and hydrophobic 
agent (simvastatin) released more slowly than hydrophilic agent (PDGF) in vivo. As 
a consequence, those properties enabled an early-release profile of PDGF followed 
by slow-release of simvastatin. On the other hand, by reversing the compartment in 
the microspheres (PDGF-in-core and simvastatin-in-shell), a parallel release profile 
of PDGF and simvastatin can be achieved.  
 
As shown in Figure 8, approximately 80% of shell-loaded protein (BSA or PDGF, 
hydrophilic agent) and 30% of core-loaded biomolecules (simvastatin, hydrophobic 
agent) were released at day 7. This result was in accordance to the previous study 
which investigated the release of a hydrophobic drug paclitaxel and a hydrophilic 
drug suramin from PLGA/PLLA core-shell microspheres [122, 126], whereas the 
paclitaxel-in-the-core and suramin-in-the-shell microspheres showed a sequential 
release of suramin followed by paclitaxel, and suramin-in-the-core and 
paclitaxel-in-the-shell microspheres displayed a parallel release profile. Similar 
results on the combination of paclitaxel and carboplatin in PLGA/PLLA 







5.2 Biocompatibility of microspheres 
The basic criteria of implantable material for medical device should be biocompatible, 
inert and safe [127]. In this sense, investigations for biocompatibility mainly aimed on 
cell viability and destructive inflammatory profiles [128, 129]. Poly(lactic-acid) and 
poly(glycolic-acid) are generally degraded by hydrolysis and the degradation products 
can stimulate transient inflammation and formation of fibrous microcapsules [127]. 
The inflammation can be reduced by slowing down the degradation rate but will not 
resolve until the disappearance of the polymer fragments [130]. In the present study 
herein, only a low-level of inflammation was observed within the implanted area 
enabling the present microspheres to be suitable for dentoalveolar regeneration 
(Figures 13 and 16).   
 
XP-treated-specimens demonstrated elevated PCNA expression and reduced cell 
death (Figure 16), indicating that the PDGF was biologically active and our 
microspheres were able to support PDGF-mediated cellular activities. Persistent 
reduction of apoptosis until day 14 implies that PDGF may overcome the tissue 
reaction elicited by the degradation products of PLGA (PDLLA). It was not surprising 
that the proliferation recessed at day 14, where more than 80% of PDGF had been 





A reduction of apoptosis and inflammation was also noted in SB-treated-specimens. 
Studies had indicated that statins may reduce inflammation through the regulation of 
cellular behavior as well as reduction of inflammatory cytokines [131, 132]. 
Simvastatin had been demonstrated to perform osteoinduction in several in vitro 
studies [75, 133], however, the in vivo studies have been limited to the change of 
quality of bone or osseous wound repair models [87, 134, 135]. In this study, 
simvastatin was subcutaneously implanted and the results revealed that simvastatin is 
unlikely to induce ectopic osteogenesis. This finding was similar to the previous study, 
which reported that subcutaneous delivery of statins can neither elicit ectopic 
calcification nor significant toxicity or inflammation [136]. On the other hand, 
Sugiyama et al. [137] reported that BMP-induced ectopic bone formation was 
augmented in combination with simvastatin. Taken together, simvastatin appears to 
present an osteopromotive rather than osteoinductive effect in vivo. The efficacy 
should be evaluated with the presence of other osteoinductive factors. 
 
The dual-biomolecules delivery systems (PS- and SP-microspheres) demonstrated 
further improvement on biocompatibility (Figures 9-19). Specifically, parallel release 
of PDGF and simvastatin (PS-microspheres) can significantly reduce cell death. This 





cytokines and upregulating anti-apoptotic signaling pathways, respectively [132]. The 
SP-treated-specimens demonstrated significant and persistent enhancement of 
proliferation, indicating the prominent mitogenesis effect of PDGF in early stages, 
and the subsequent release of simvastatin in later stage can render a suitable 
environment for angiogenesis and tissue repair, indirectly favoring the growing of 
mesenchymal and endothelial cells [138].  
 
5.3 In Vivo Efficacy 
At day 14, generalized osteogenesis was observed in XP-treated specimens, but 
SB-treated-specimens showed only scattered osteogenesis (Figure 24D). This result 
could be associated with the promotion of stem cells recruitment and proliferating by 
PDGF [139]. Due to the lack of molecular signaling for cell recruitment in the early 
stages of regeneration, only a slight increase in mineralization was noted in the 
SB-treated specimens. Limited numbers of cells with differentiation capability within 
the defect could still impede regeneration in the later stage. While the recruitment and 
mitogenesis of stem cells were the dominant event in the early stage of wound healing 
[140], fast release of PDGF within the first week of delivery may reasonably augment 
these events. On the other hand, we also noted that osteogenesis took place close to 





of osteogenesis, via the activation of the Smad pathways and BMP-signaling [82]. In 
contrast, without direct involvement in BMP-signaling, the distance between the front 
of osteogenesis and PDGF-loaded microspheres was greater [141] (Figure 24D).  
 
The dual-biomolecules delivery systems (PS- and SP-microspheres) demonstrated 
further improvement on bone-forming at day 14 (Figure 22). The 
PS-treated-specimens demonstrated significant increase of newly-formed bone and 
trabecular number than the control. This may due to the synergetic effect of PDGF on 
cells recruitment and proliferation [139] and the induction of cells differentiation by 
simvastatin [80]. The SP-treated-specimens showed the highest increase in 
newly-formed bone, trabecular thickness and trabecular number. This indicated that 
sequential release of PDGF and simvastatin can further improve bone regeneration 
due to timely augmentation of proliferation and differentiation by mimicking the 
physiological events. In a previous study, the combination of PDGF and BMP-7 
expressed by adenovirus vectors on chitosan/collagen scaffolds has also demonstrated 
synergetic bone-forming effects in a dog model [142]. However, sequential release of 
PDGF and BMP-7 was not investigated in this study. In this study, we used 
simvastatin, a clinical drug, to replace the differentiation factor, BMP. The 





of two biomolecules with a desire profile. 
 
At day 28, elevated bone growth was noted in SB- and XP-treated-specimens (Figures 
23 and 25). This may due to gradually increase of progenitor cells and endogenous 
signals within the defect at the later stage. Since PDGF is not directly involved in 
osteogenic differentiation, the osteogenesis in XP-treated-specimens was only 
promoted at day 28. On the other hand, simvastatin promoted osteogenic 
differentiation with limited effects on cell recruitment, the osteogenesis of simvastatin 
treatment was limited at the early stage. The SP-treated-specimens demonstrated 
nearly 40% of bone growth whereas limited bone formation was found in the 
PS-treated-specimens (Figures 23 and 25). This revealed that parallel release of PDGF 
and simvastatin may prevent subsequent bone growth at the later stage. Given that 
PDGF did not elicit the differentiation potential of cells, and consistent expression of 
PDGF may prevent stem cells from differentiation and retard the maturation of bone 
[143, 144], tissue mineralization might remain primitive and limited in the later stage 
if PDGF was still in effect. Due to the minimal level of PDGF in the 
SP-treated-specimens in later stages, the inhibition of osteogenesis could be prevented, 
leading to continuous bone growth and maturation at day 28. 
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Conclusions and Future Perspective 
 
6.1 Conclusions   
1. We successfully fabricated double-walled microspheres which sequentially 
released PDGF and simvastatin when encapsulated PDGF in the shell and 
simvastatin in the core. Moreover, parallel released of PDGF and simvastatin 
can also be achieved by encapsulating PDGF in the core and simvastatin in the 
shell. 
 
2. The fabricated microspheres were biocompatible and biologically active. 
 
3. Sequential PDGF and simvastatin can promote dentoalveolar bone formation 
and maturation in the preclinical model.  
 
6.2 Future perspective 
Although PDGF was delivered to promote cell proliferation and recruitment, local 
stem cells may be damaged or lack the ability to differentiate into osteogenic cells in 
the defects. In this regard, providing exogenous cells may be needed [145, 146]. Thus, 




combination of exogenous cells with controlled bioactive molecules releasing profiles 
could be considered to further optimize the outcome of regeneration [142]. On the 
other hand, according to that PDGF and simvastatin had been FDA-approved and 
available for clinical use in Singapore, further investigations in large animals or early 






















Figure 1. Schematic illustration of the tooth-supporting apparatus in normal 
periodontium. 
 
The normal periodontium comprised of gingiva, alveolar bone, cementum, and 








Figure 2. Phases of wound healing. 
 












































Figure 4. Animal study design and defect creation  
 
(A) The study design. Critical-sized osseous defects was created after 4 weeks of 
socket wound healing and filled with microspheres (encapsulating XB, SB, XP, PS 
and SP). The maxillae were extracted after 14 (D14) and 28 days (D28) of 
microspheres filling. (B) The osseous defect created in the edentulous ridge after the 
extraction of maxillary first molar (M1).  









Figure 5. The selection of ROI for quantitative micro-CT measurement. 
 
(A) The transverse plane. Yellow dash line indicates the ROI. Native bone and 
newly-formed bone. (B) The sagittal plane. After selection of ROI from transverse 
plane, a horizontal line (red dotted line) was drawn at the sagittal plane according to 
the edge of the alveolar bone around the defect and a vertically 1mm in depth from 
the edge was automatically selected. The whole stack of ROI will be selected 









Figure 6. Morphology of double-walled microspheres. 
 
SEM images of microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core 
and BSA-in-shell (SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and 









Figure 7. Morphology of double-walled microspheres.  
 










Figure 8. In vitro release profile of each group from day 1 to day 14.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 










Figure 9. Histology of double-walled microspheres after 10 days implantation, 
x100.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 









Figure 10. Histology of double-walled microspheres after 14 days implantation, 
x100.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 









Figure 11. PCNA staining for proliferating cells at day 10, x 400.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 
simvastatin-in-core and PDGF-in-shell (SP). Positive cells appeared in brownish color. 









Figure 12. TUNEL staining for apoptotic cells at day 10, x 400.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 
simvastatin-in-core and PDGF-in-shell (SP). Positive cells appeared in brownish color.  








Figure 13. Quantitative data for in vivo cell viability after 10 days of 
implantation. 
 









Figure 14. PCNA staining for proliferating cells at day 14, x 400.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 
simvastatin-in-core and PDGF-in-shell (SP). Positive cells appeared in brownish color. 









Figure 15. TUNEL staining for apoptotic cells at day 14, x 400.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 
simvastatin-in-core and PDGF-in-shell (SP). Positive cells appeared in brownish color. 








Figure 16. Quantitative data for in vivo cell viability after 14 days of 
implantation. 
 








Figure 17. Fibrotic wall around the microspheres at 10 days after implantation,  
x 100.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 
simvastatin-in-core and PDGF-in-shell (SP). Red-arrows indicate fibrotic wall around 








Figure 18 Fibrotic wall around the microspheres at 14 days after implantation,  
x 100.  
 
Microspheres with (A) BSA-in-shell (XB) (B) simvastatin-in-core and BSA-in-shell 
(SB) (C) PDGF-in-shell (XP) (D) PDGF-in-core and simvastatin-in-shell (PS) (E) 
simvastatin-in-core and PDGF-in-shell (SP). Red-arrows indicate fibrotic wall around 








Figure 19. Quantitative data for the thickness of fibrotic wall around the 
microspheres after 10 and 14 days of implantation.  
 














Figure 20. Transverse plan of micro-CT images in each group.  
 
(A) 14 days and (B) 28 days after defect creation. White dashed-line indicated the 















Figure 21. Saggital plan of micro-CT images in each group.  
 










Figure 22. The micro-CT quantitative results of specimens at 14 days after 
surgery.  
 
Each group was compared to XB (#) and control without any microspheres (*, Ctrl)). 








Figure 23. The micro-CT quantitative results of specimens at 28 days after 
surgery.  
 
Each group was compared to XB (#) and control without any microspheres (*, Ctrl)). 









Figure 24. Descriptive histology images of each group at 14 days after 
implantation, x 200.  
 
(A) Non-microspheres control and microspheres with (B) BSA-in-shell (XB) (C) 
simvastatin-in-core and BSA-in-shell (SB) (D) PDGF-in-shell (XP) (E) 
PDGF-in-core and simvastatin-in-shell (PS) (F) simvastatin-in-core and 
PDGF-in-shell (SP). (Scale bar represents 100µm). Abbreviation: Asterisk: polymer 









Figure 25. Descriptive histology images of each group at 28 days after 
implantation, x 200.  
 
(A) Non-microspheres control and microspheres with (B) BSA-in-shell (XB) (C) 
simvastatin-in-core and BSA-in-shell (SB) (D) PDGF-in-shell (XP) (E) 
PDGF-in-core and simvastatin-in-shell (PS) (F) simvastatin-in-core and 
PDGF-in-shell (SP). (Scale bar represents 100µm). Abbreviation: Asterisk: polymer 







Table 1 Summary of the fabricated double-walled microspheres of different 
loaded biomolecules and their encapsulation efficiencies 
 
 
EE, encapsulation efficiency; BSA, bovine serum albumin; PDGF, platelet-derived growth factor; 
microspheres with BSA-in-shell (XB); simvastatin-in-core and BSA-in-shell (SB); PDGF-in-shell 
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